Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Ipilimumab and tremelimumab are human monoclonal antibodies (Abs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival in advanced melanoma patients. Currently, there is no proven association between the BRA...

Full description

Bibliographic Details
Main Authors: Mangana, Joanna, Cheng, Phil F., Schindler, Katja, Weide, Benjamin, Held, Ulrike, Frauchiger, Anna L., Romano, Emanuella, Kähler, Katharina C., Rozati, Sima, Rechsteiner, Markus, Moch, Holger, Michielin, Olivier, Garbe, Claus, Hauschild, Axel, Hoeller, Christoph, Dummer, Reinhard, Goldinger, Simone M.
Format: Online
Language:English
Published: Public Library of Science 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591284/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591284/

Similar Items